Monthly research briefings.

Mechanism-anchored summaries of currently-running peer-reviewed peptide research, with full citations to PubMed and ClinicalTrials.gov. Built for qualified researchers who want a signal-only feed of what's happening in the pipeline.

Issue 002July 2026

Beyond GLP-1: New Frontiers

CagriSema's Phase 3 REDEFINE readouts (amylin + GLP-1 combination), and elamipretide — the first FDA-approved cardiolipin-binding mitochondrial peptide.

Issue 001June 2026

The Incretin Pipeline

Retatrutide (LY3437943, GLP-1/GIP/glucagon triagonist) and survodutide (BI 456906, GLP-1/glucagon dual agonist) — the next generation of multi-receptor incretin research.

← Back to pepguidance.com